Heron Therapeutics(US:HRTX) Globenewswire·2026-02-26 13:00Core Insights - Heron Therapeutics reported a 65% year-over-year net revenue growth in its Acute Care franchise, achieving $154.9 million in net revenue for 2025 and providing guidance for 2026 net revenue between $173 million and $183 million, with adjusted EBITDA expected to be between $10 million and $20 million [1][3]. Financial Performance - The Acute Care franchise experienced a revenue growth of 57.3% year-over-year in Q4 2025 and 65.1% for the full year 2025 compared to 2024, indicating strong commercial acceleration [4]. - Total net revenue for 2025 was $154.9 million, up from $144.3 million in 2024, reflecting a 7.4% increase [9]. - For Q4 2025, total net revenue was $40.6 million, slightly down from $40.8 million in Q4 2024, marking a 0.5% decrease [10]. Product Updates - ZYNRELEF, a key product, received a permanent product-specific J-Code (J0668) from CMS, effective October 1, 2025, which streamlines reimbursement processes [7]. - The transition to the Vial Access Needle for ZYNRELEF has been completed, enhancing product handling and sterility in hospitals and surgical centers [7]. - APONVIE, another significant product, was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its clinical importance [7]. Market Position and Strategy - The CEO emphasized that the company is entering 2026 with strong momentum, driven by strategic decisions that have unlocked the potential of its assets, particularly ZYNRELEF [2]. - The company is focused on expanding demand signals and improving reimbursement clarity, positioning itself for continued market share gains and revenue growth in 2026 and beyond [2]. Oncology Franchise - The Oncology franchise generated over $105 million in net revenue for 2025, despite facing complex market dynamics [8].